Danish drugmaker Novo Nordisk has teamed up with Emcure Pharmaceuticals to increase access to its weight-loss drug semaglutide in India, introducing it as a second brand, Poviztra. The collaboration aims to enhance accessibility in the competitive anti-obesity market.